{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-24-000012","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.355525+00:00","generated_at":"2026-06-06T08:21:38.729256+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rallybio cuts 45% of workforce, extends cash runway to mid-2026","bullets":["Workforce reduction of 45% (19 positions); expects ~$3.3M in severance charges.","Preliminary cash, equivalents and marketable securities of $109.9M as of Dec 31, 2023.","Prioritizes Phase 2-ready programs RLYB212 (FNAIT) and RLYB116 (C5 inhibitor).","Cash runway extended into mid-2026; preclinical programs seek alternative funding.","RLYB212 Phase 2 update with EMA expected H1 2024; Phase 2 initiation in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-24-000012","json":"https://secwatch.observer/filing/0001739410-24-000012.json","markdown":"https://secwatch.observer/filing/0001739410-24-000012.md","text":"https://secwatch.observer/filing/0001739410-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/0001739410-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/rlyb-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:21:38.729256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"839371e27dba10ed767000a89ca8700dbbb2825f","claim":"Rallybio Corp announced a restructuring with charges of approximately $3.3 million affecting Rallybio (approximately 45% of its current positions).","evidence_excerpt":"On February 6, 2024, Rallybio announced the prioritization of its portfolio and a workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116. As part of this effort, Rallybio will eliminate approximately 45% of its current positions. As a result of these actions, Rallybio expects to incur charges of approximately $3.3 million, excluding share-based compensation expense.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/0001739410-24-000012-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.3 million"},{"label":"Affected area","value":"Rallybio"},{"label":"Headcount","value":"approximately 45% of its current positions"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}